valproic acid has been researched along with ALS - Amyotrophic Lateral Sclerosis in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SH; Gyawali, A; Hyeon, SJ; Kang, YS; Latif, S; Ryu, H | 1 |
| Bankole, O; Bonafede, R; Mariotti, R; Muccilli, M; Parrella, E; Pizzi, M; Scambi, I; Turano, E | 1 |
| Al-Dardery, NM; Attia, AN; Hamad, AA; Meshref, M; Mohamed, SF | 1 |
| Alcaraz-Zubeldia, M; Bayliss, L; Boll, MC; Burgos, J; Montes, S; Peñaloza-Solano, G; Rios, C; Vargas-Cañas, S | 1 |
| Keum, G; Kowall, NW; Lee, J; Ryu, H; Yoon, YJ | 1 |
| Dong, GT; Feng, HL; Jiang, HQ; Jiang, HZ; Qi, Y; Ren, M; Wang, J; Wang, SY; Wang, TH; Wang, XD; Yang, YQ; Yin, X | 1 |
| Che, X; Ding, X; Feng, S; Ma, M; Teng, J; Wang, X; Wu, E; Zhang, W; Zhang, Y; Zhou, S | 1 |
| Feng, HL; Jiang, HQ; Jiang, HZ; Qi, Y; Wang, J; Wang, SY; Wang, TH; Wang, XD; Wang, Y; Yang, YQ; Yin, X; Zhang, CT | 1 |
| Chuang, DM; Feng, HL; Leng, Y; Ma, CH; Ren, M; Zhang, J | 1 |
| Bonamassa, B; Canistro, D; Contestabile, A; Crochemore, C; Paolini, M; Pena-Altamira, E; Virgili, M | 1 |
| de Jong, JM; de Jong, SW; de Visser, M; Groeneveld, GJ; Piepers, S; Scheffer, H; Schelhaas, HJ; Uijtendaal, EV; van den Berg, LH; van der Pol, WL; van der Tweel, I; Veldink, JH; Wokke, JH | 1 |
| Goto, M; Hamasaki, T; Miyaguchi, K; Sakoda, S; Sugai, F; Sumi, H; Yamamoto, Y; Zhou, Z | 1 |
| Di Francesco, JC; Ferrarese, C; Rodriguez-Menendez, V; Sala, G; Tremolizzo, L | 1 |
| Boutillier, AL; Dupuis, L; Echaniz-Laguna, A; Gonzalez de Aguilar, JL; Loeffler, JP; Menger, Y; Panteleeva, I; René, F; Rouaux, C | 1 |
2 review(s) available for valproic acid and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Safety and efficacy of lithium in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Amyotrophic Lateral Sclerosis; Humans; Lithium; Randomized Controlled Trials as Topic; Valproic Acid; Vital Capacity | 2023 |
Therapeutic targeting of epigenetic components in amyotrophic lateral sclerosis (ALS).
Topics: Amyotrophic Lateral Sclerosis; Animals; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Motor Neurons; Superoxide Dismutase; Superoxide Dismutase-1; Valproic Acid | 2014 |
1 trial(s) available for valproic acid and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Genotype; Histone Deacetylase Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Motor Neurons; Sequence Analysis, DNA; Severity of Illness Index; Survival of Motor Neuron 1 Protein; Survival of Motor Neuron 2 Protein; Treatment Outcome; Valproic Acid | 2009 |
11 other study(ies) available for valproic acid and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Monocarboxylate transporter functions and neuroprotective effects of valproic acid in experimental models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Mice; Mice, Transgenic; Monocarboxylic Acid Transporters; Motor Neurons; Neuroprotective Agents; Superoxide Dismutase; Symporters; Valproic Acid | 2022 |
Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice.
Topics: AMP-Activated Protein Kinases; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Female; Histone Deacetylase Inhibitors; Histones; Male; Mice; Mice, Transgenic; NF-kappa B; Resveratrol; Sirtuin 1; Superoxide Dismutase; Valproic Acid | 2022 |
Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Cadmium; Cause of Death; Disability Evaluation; Enzyme Inhibitors; Female; Follow-Up Studies; Glutathione; Glutathione Peroxidase; Humans; Kaplan-Meier Estimate; Lithium Carbonate; Male; Middle Aged; Statistics, Nonparametric; Superoxide Dismutase; Superoxide Dismutase-1; Valproic Acid | 2014 |
Notch pathway is activated in cell culture and mouse models of mutant SOD1-related familial amyotrophic lateral sclerosis, with suppression of its activation as an additional mechanism of neuroprotection for lithium and valproate.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Gene Expression Regulation; Humans; Lithium Chloride; Mice; Mice, Transgenic; Motor Neurons; Neuroprotective Agents; Receptors, Notch; RNA, Small Interfering; Signal Transduction; Spinal Cord; Superoxide Dismutase; Transfection; Valproic Acid | 2015 |
Valproate Attenuates 25-kDa C-Terminal Fragment of TDP-43-Induced Neuronal Toxicity via Suppressing Endoplasmic Reticulum Stress and Activating Autophagy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Autophagy; Cell Line; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Flow Cytometry; Immunoblotting; Mice; Neurons; Peptide Fragments; Tetrazolium Salts; Thiazoles; Valproic Acid | 2015 |
Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.
Topics: Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Cell Line; Genetic Predisposition to Disease; Homer Scaffolding Proteins; Humans; Lithium; Mice; Mice, Transgenic; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Superoxide Dismutase; Valproic Acid | 2016 |
Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
Topics: Adjuvants, Immunologic; Age Factors; Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Glycogen Synthase Kinase 3; Hindlimb Suspension; Humans; Lithium Chloride; Mice; Mice, Transgenic; Motor Activity; Muscle Strength; Mutation; Nervous System Diseases; Psychomotor Performance; Reflex; Rotarod Performance Test; Superoxide Dismutase; Survival Analysis; Valproic Acid | 2008 |
Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis.
Topics: Acetylcholinesterase; Amyotrophic Lateral Sclerosis; Animal Feed; Animals; Antineoplastic Agents; Choline O-Acetyltransferase; Disease Models, Animal; Female; GABA Agents; Gene Dosage; Humans; Life Expectancy; Male; Mice; Mice, Transgenic; Nerve Degeneration; Superoxide Dismutase; Superoxide Dismutase-1; Tretinoin; Valproic Acid | 2009 |
Benefit of valproic acid in suppressing disease progression of ALS model mice.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Cell Count; Cell Death; Dicarboxylic Acids; Disease Models, Animal; Disease Progression; Drug Interactions; Humans; Mice; Mice, Transgenic; Motor Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Organ Culture Techniques; Spinal Cord; Superoxide Dismutase; Time Factors; Valproic Acid | 2004 |
Valproate and HDAC inhibition: a new epigenetic strategy to mitigate phenotypic severity in ALS?
Topics: Amyotrophic Lateral Sclerosis; Histone Deacetylase Inhibitors; Humans; Phenotype; Valproic Acid | 2005 |
Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Line, Tumor; CREB-Binding Protein; Disease Models, Animal; Male; Mice; Mice, Transgenic; Neuroprotective Agents; Oxidative Stress; Survival Rate; Valproic Acid | 2007 |